Stoke Therapeutics expands board to 10 directors, appoints G. Clare Kahn as R&D chair

Filed April 7, 2026 · Period ending April 3, 2026 · ~1 min read

Key Changes

• medium

  Board expanded from 9 to 10 seats and appointed G. Clare Kahn, Ph.D. as Class I director effective April 3, 2026. Dr. Kahn will chair the Research & Development Committee and serve on the Nominating Committee.

  Item 5.02 verify on EDGAR →
• low

  Dr. Kahn received standard director compensation: $45,000 annual cash retainer plus initial stock option grant for 30,782 shares valued at ~$724,000, vesting quarterly over three years.

  Item 5.02 verify on EDGAR →
• low

  Board confirmed Dr. Kahn meets independence requirements under Securities Act of 1933 and Nasdaq listing standards, with no related party transactions.

  Item 5.02 verify on EDGAR →